8/3/2019 NISHA j

1/23

8/3/2019 NISHA j

2/23

INTRODUCTION

Novartis based in Basel, Switzerland was created in 1996

through the merger of Ciba-Geigy and Sandoz, twocompanies with a rich and diverse corporate history.

Throughout the years, Novartis and its predecessor

companies have discovered and developed many

innovative products for patients and consumersworldwide.

8/3/2019 NISHA j

3/23

AIM

Novartis aims to change the practice of

medicine and innovation at novartis not only

means developing effective targeted

medicines quickly but also ensuring that these

medicines get to the patients who need them.

8/3/2019 NISHA j

4/23

INNOVATION AT NOVARTIS

Growing need for innovation in healthcare

Rapid aging of the population, greater access to healthcarein emerging markets and advances in science create

opportunities to enhance the lives of patients throughinnovation.

Healthcare innovation generally refers to the drugdiscovery and development process the translation of

fundamental science into new drugs, vaccines, devices anddiagnostic tests. This type of innovation requires significantinvestment and teams commanding specialized, yetcomplementary skills.

8/3/2019 NISHA j

5/23

Innovation at Novartis

Our strategy of focused diversification helps us tocapitalize on this changing healthcareenvironment while balancing risk. Novartis has

leading businesses in science-based, fast growingsegments of healthcare.

Novartis aims to change the practice of medicine,and innovation at Novartis not only means

developing effective, targeted medicines quickly,but also ensuring that these meet the need ofpeople .

8/3/2019 NISHA j

6/23

MISSION

8/3/2019 NISHA j

7/23

MISSION

We want to discover, develop and successfullymarket innovative products to prevent and curediseases, to ease suffering and to enhance the

quality of life. We also want to provide a shareholder return

that reflects outstanding performance and toadequately reward those who invest ideas and

work in our company.

8/3/2019 NISHA j

8/23

Healthcare portfolio

We believe our portfolio best meets the varied andoften complex needs of patients and societies. Novartisis positioned to lead in innovation, partner with othersand offer solutions to patients across a broadhealthcare spectrum. In addition, a diverse portfolioreduces financial risk, bringing greater value to thosewho invest in our company.

Our unique portfolio focuses on science-based

healthcare sectors that are growing rapidly, rewardinnovation, and enhance the lives of patients.

8/3/2019 NISHA j

9/23

KEYAREAS

Novartis is the only company with leading positions ineach of these key areas:

Pharmaceuticals: innovative patent-protectedmedicines

Alcon: global leader in eye care with surgical,ophthalmology and consumer products

Sandoz: affordable, high-quality generic medicines andbiosimilars

Consumer Health: self-medication products andtreatments for animals

Vaccines and Diagnostics: vaccines and diagnostictools to protect against life-threatening diseases

8/3/2019 NISHA j

10/23

Business strategy

Innovation is flourishing, bringing new effective treatmentsto patients. There are significant challenges, however, andthe healthcare environment is undergoing unprecedented

change. The world's population is aging. Better healthcare

treatments are needed, also prompting payors to managecosts aggressively. Advancing science and technology areenabling new drug discovery while increasing the cost of

innovation.E

conomic growth in emerging countries isproviding better healthcare access, but the poorest still lackbasic medicines. Changing lifestyles are leading to higherprevalence of chronic and degenerative diseases.

8/3/2019 NISHA j

11/23

PRODUCTS

Pharmaceuticals

Alcon (eye care)

Vaccines and Diagnostics

Over-the-Counter

Animal Health

Sandoz (generics)

8/3/2019 NISHA j

12/23

Pharmaceuticals

Innovating to treat disease more effectively

Their globalP

harmaceuticals portfolio includesmore than 60 key marketed products, many of

which are innovative leaders in their therapeutic

areas. In 2010 they received a total of 13 major

approvals and made 16 regulatory submissions inthe United States, Europe and Japan.

8/3/2019 NISHA j

13/23

Alcon (eye care)

Novartis proposes to complete purchase of majority ofstake in Alcon, followed by direct merger of alcon intonovartis.

Products to enhance, preserve and restore vision

Alcon's mission is to provide innovative products thatenhance quality of life by helping people see better.

Alcon's leadership in eye care is founded inpharmaceutical and surgical products as well as over-

the-counter ophthalmic products - including contactlens care - with differentiated technology, createdthrough dedicated research and development

The integration of CIBA Vision into Alcon adds acomprehensive contact lens and lens care business to

Alcon's current portfolio

8/3/2019 NISHA j

14/23

Sandoz (Generics)

Delivering affordable, high-quality medicines

Sandoz, the generic pharmaceuticals division ofNovartis, is a global industry leader, offeringaffordable, high-quality medicines to everyone,everywhere. It is the second-largest division of

Novartis.

2010 net sales - USD 8.5 billion

Number 3 in sale of Sandoz

8/3/2019 NISHA j

15/23

8/3/2019 NISHA j

16/23

Over-the-Counter

Novartis OTC (Over-the-Counter) is a world leader in theresearch, development, production and marketing of self-medication products that do not require prescriptions. Ourproducts are designed for in-home treatment and prevention

of medical conditions and ailments to enhance health andimprove life every day.

Novartis OTC has a robust portfolio of cough, cold, respiratorydisease, digestive health and pain management medication as

well as analgesics, skin care products, smoking-cessationtreatments and mineral supplements

8/3/2019 NISHA j

17/23

Vaccines and Diagnostics

Preventing diseases with innovative products

The Novartis Vaccines and Diagnostics Divisionprovides more than 20 products to fight vaccine-preventable viral and bacterial diseases as well assophisticated instruments, assays and software to testdonated blood for infectious diseases before use intransfusions or other medical therapies.

The division consists of two businesses:

Novartis Vaccines ,Novartis Diagnostics

8/3/2019 NISHA j

18/23

Novartis Animal Health Products

Advancing animal healthcare

Novartis Animal Health is a leader indeveloping new and better ways to preventand treat diseases in pets, farm animals andcultivated fish. Our innovative, high-quality

medicines contribute to the quality of life,health and welfare of animals around theworld.

8/3/2019 NISHA j

19/23

Our culture

At Novartis, our performance-oriented culture andresponsible approach are the foundations of our success.We recognize that our business depends on the creativity,dedication and performance of our associates. We

encourage associates to focus on achievement throughcollaboration and innovation.

A global healthcare leader, Novartis has one of the mostexciting product pipelines in the industry today. A pipeline

of innovative medicines brought to life by diverse, talented,performance driven people. All of which makes us one ofthe most rewarding employers in our field.

8/3/2019 NISHA j

20/23

ASSOCIATES

With more than 1,15 ,000 associates in 140

countries worldwide, Novartis associates share a

vision ofa better today and tomorrow forpatients a vision that drives our growth andsuccess. The greatest job satisfaction for ourassociates is the knowledge that they improve

the quality of life for patients with increasingprecision and efficiency through breakthroughscience and innovation.

8/3/2019 NISHA j

21/23

Collaborations

The path from scientific breakthrough tosuccessful pharmaceutical brand depends onmobilizing the best global resources, expertise

and experience. At Novartis, we often achieve success

through close collaboration with partners whoshare a common vision and complementary

strengths. A key Novartis priority is to buildwinning collaborations in the research of newmedicines and vaccines.

8/3/2019 NISHA j

22/23

FOCUS

Our focus is on patients they are the reason

for what we do. During 2009 medicines and

vaccines from Novartis were used to treat and

protect more than 930 million people

worldwide, according to internal estimates.

8/3/2019 NISHA j

23/23